Evaluation of Two Rapid Lateral Flow Tests and Two Surrogate ELISAs for the Detection of SARS-CoV-2 Specific Neutralizing Antibodies
Open Access
- 4 February 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 820151
Abstract
As vaccination against SARS-CoV-2 progresses rapidly around the world, reliable detection of SARS-CoV-2 specific neutralizing antibodies (NAb) has become an indispensable component of serological diagnostics. We evaluated the performance of four commercially available tests, i.e. two lateral flow assays (Coris BioConcept COVID-19 Sero NP/RBD and Concile InfectCheck COVID-19 NAb) and two surrogate ELISA (sELISA) tests (EUROIMMUN SARS-CoV-2 NeutraLISA and AdipoGen SARS-CoV-2 Neutralizing Antibodies Detection Kit) in comparison with an in-house SARS-CoV-2 micro neutralization test as reference. A total of 334 sera were tested, including 30 samples collected prior to the emergence of SARS-CoV-2, 128 sera from convalescent patients as well as 176 sera from partially or fully vaccinated individuals. The overall sensitivity of LFAs differed and was 71.6% for the Coris and 98.4% for the Concile. In contrast, overall sensitivity of the NeutraLISA was 86 and 98% for the AdipoGen. All test showed the highest sensitivity when testing samples from fully vaccinated individuals with both sELISA achieving 100% sensitivity. Overall specificity was 89.3% for the Coris and only 58.3% for the Concile. Similarly, significant differences were observed for both sELISA, with an overall specificity of 82.1% for the NeutraLISA and only 54.8% for the AdipoGen. All tests showed a 100% specificity when testing negative control samples while specificities were lowest when testing samples from only partially vaccinated individuals.Keywords
This publication has 34 references indexed in Scilit:
- Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparisonThe Lancet Infectious Diseases, 2020
- Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitroBiosafety and Health, 2020
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategiesNature, 2020
- Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testingClinical Chemistry and Laboratory Medicine (CCLM), 2020
- Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of AntibodiesCell, 2020
- An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessmentNature Communications, 2020
- Towards the next phase: evaluation of serological assays for diagnostics and exposure assessmentmedRxiv, 2020
- Evaluation of nine commercial SARS-CoV-2 immunoassaysmedRxiv, 2020
- Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2Emerging Microbes & Infections, 2020